US Stock MarketDetailed Quotes
ITRM Iterum Therapeutics
- 1.5799
- -0.0201-1.26%
Trading May 9 15:39 ET
26.16MMarket Cap-533P/E (TTM)
1.6200High1.5600Low55.40KVolume1.5900Open1.6000Pre Close88.15KTurnover0.36%Turnover RatioLossP/E (Static)16.55MShares2.500052wk High-4.08P/B24.43MFloat Cap0.622052wk Low--Dividend TTM15.46MShs Float195.0000Historical High--Div YieldTTM3.75%Amplitude0.6010Historical Low1.5910Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Iterum Therapeutics Stock Forum
NEWS
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
Dow Jones· 2 mins ago
In today's volatile market, discerning investors are constantly on the lookout for promising ventures that offer a strong return potential. One such opportunity that has piqued interest is Iterum Therapeutics (NASDAQ: $ITRM), a clinical-stage pharmaceutical company focused on developing anti-infectives to combat multi-drug resistant pathogens. Recently, HC Wainwright...
• The company said that the filing would address the concerns the regulator raised in July 2021 when it declined to approve the product. At the time, the company targeted sulopenem for patients with urinary tract infections caused by quinolone non-susceptible pathogens.
...
No comment yet